BGPT: Paper Review: DnaJB1 chaperone inhibits tau aggregation by recognizing its N-terminus

Explore by Goal

Quick Explanation Copied

Core result

DnaJB1 inhibits full-length (FL) tau aggregation in heparin-free conditions by recognizing negatively charged N-terminal “fuzzy coat” motifs; however, when heparin is present, DnaJB1’s binding is enhanced yet its suppression of seed emergence is reduced/lost, implying a context-dependent and potentially competitive binding mechanism.

Evidence is supported by cellular tau-seeding FRET assays, heparin/no-heparin in vitro ThT kinetics, weak transient binding mapping (NMR, ITC/MST/SEC), and interaction-site discovery via XL-MS. ()

Long Explanation

Paper Review (Evidence-First): DnaJB1 chaperone inhibits tau aggregation by recognizing its N-terminus

Date context: The manuscript appears as a 2025 bioRxiv/medRxiv-style preprint identifier 10.1101/2025.10.02.680111.

Principal mechanistic claim: DnaJB1 preferentially acts through tau’s N-terminal acidic “fuzzy coat” in heparin-free conditions, but heparin alters the binding/functional outcome (enhanced recruitment yet diminished suppression of seed formation).

Figure A — Mechanistic logic (as argued by the authors)

Heparin-free

DnaJB1 inhibition of FL tau aggregation and seed emergence is N-terminus dependent.
Weak/transient interaction sites map to tau N-terminal acidic motifs (fuzzy coat).

With heparin

DnaJB1:tau binding is enhanced by heparin (likely bridging/multivalency).
Yet functional inhibition of seeds is lost/reversed at heparin-containing conditions, implying altered binding modes/competition.

Domains they propose for recognition

DnaJB1 JD participates in recruitment to tau.
CTDI/CTDII interface (hinge) provides additional tau-contact contributions (mapped by XL-MS, supported by heparin-dependent contact differences).

Skeptical note: this logic diagram is a faithful restatement of the authors’ interpretation. Several readouts (ThT vs cellular inclusions) can diverge, so the causal link “heparin-enhanced binding ⇒ seed suppression loss” may involve multiple concurrent mechanisms (e.g., masking of heparin-linked surfaces, altered fibril polymorphs, or different seed species being detected).

Figure B — Experimental flow (cell & in vitro) as described

Cellular tau seeding (FRET flow cytometry)

Transfect HEK293T with DnaJB1 overexpression plasmid or siRNA KD (~48 h expression window).
Co-transfect N-terminal truncation constructs of 2N4R tau fused to mEOS3.2/mCerulean3 readout.
Seed with exogenous tau fibrils (heparin-induced or heparin-less via S320F + buffer conditions) at defined monomer concentration.
Read out tau aggregate/seeding by FRET-positive percentage after fixation (48 h post-seeding).

In vitro aggregation & binding mapping

ThT kinetics for FL tau S320F and tauRD WT in buffers either heparin-free (potassium phosphate/citrate + citrate conditions) or heparin-containing (PBS + DTT + equimolar heparin18).
Binding assays: ITC, MST, NMR HSQC titrations with tau1-243, and SEC to infer heparin-linked complexes.
Interaction-site mapping: XL-MS with DSS (Lys-Lys) and DMTMM (Lys-Asp/Glu) plus modeling of DnaJB1 dimer topology (AlphaFold2/ColabFold and PDB template context).

Figure C — Evidence triangulation grid (what supports what?)

Question	What the paper measured	Support strength (internal)
Does N-terminal tau mediate DnaJB1 effects?	N-terminal truncation series + DnaJB1 OE/KD; readout: %FRET+ cells for seeded aggregation.	Moderate (clear dependence on retained acidic N-terminus regions; quantitative exactness limited by missing full numeric trace in the provided text).
Is DnaJB1 inhibition heparin-dependent?	ThT endpoint + t1/2 fits for FL tau S320F and tauRD; heparin/no-heparin conditions.	Moderate (the heparin switch is conceptually compelling, but ThT↔cell seeding species mismatch is a key caution).
Does heparin increase DnaJB1:tau binding?	ITC for DnaJB1:tau + heparin preincubation; heparin alone binds DnaJB1 (KD reported); NMR HSQC for tau1-243 titration with DnaJB1.	Moderate (binding is weak/transient without heparin; heparin-induced affinity detectable).
Where are the interaction interfaces?	XL-MS with DSS and DMTMM; mapped onto DnaJB1 domain model; HSQC peak broadening defines tau1-243 segments.	Moderate (crosslinking is proximity-based; also the G/F region lacks lysines and is “invisible” to DSS XL-MS).

Figure D — The “fuzzy coat” as a binding surface (context from prior tau structural work)

The paper’s N-terminal recognition model is consistent with the idea that pathological tau fibrils expose an electrostatic “fuzzy coat” that behaves like a polyelectrolyte brush and can include two-layered charged substructures.

Additionally, heparin can induce tau aggregation with structural polymorphs that may not match ex vivo disease fibrils; the paper explicitly uses that as motivation to test whether chaperone recognition depends strongly on heparin-based seed conditions.

Main mechanistic claims (skeptical, evidence-based)

1) DnaJB1 suppression of FL tau aggregation/seeding depends on tau’s N-terminal charge-containing region.

In the cellular biosensor system, DnaJB1 overexpression inhibited aggregation readouts for longer N-terminal tau constructs, and effects were strongly altered by truncations that change charge distribution in a region around the transition between residues ~120–140 in the 2N4R isoform.

Blind spot: because the provided text does not include the full numerical traces for each truncation, confidence in effect size ordering across all constructs is moderate, even if directionality appears consistent.

2) In heparin-free in vitro conditions, DnaJB1 inhibits FL tau fibrilization (ThT) and delays kinetics; tauRD shows different endpoints.

The paper reports a concentration-dependent inhibition of FL tau fibrilization by DnaJB1 in heparin-less buffers (with a tau:DnaJB1 ratio around 5:1 yielding near-abolition of ThT-positive fibril formation), while tauRD inhibition is described as delayed but with more variable ThT endpoint behavior.

Skeptical interpretation: ThT can reflect amyloid-beta-sheet accessibility and is not a direct measure of “seed potency.” The paper itself observes discrepancies between ThT endpoints and cellular seeding.

3) Heparin enhances DnaJB1 recruitment/binding to tau, but DnaJB1’s suppression of seeding is reduced/lost.

The paper reports that ITC detects DnaJB1 binding when tau monomers are preincubated with heparin, and heparin binds DnaJB1 with a nanomolar KD. Cellular seeding and/or seeding-competent species outputs show that the suppression of seed emergence is lost in heparin-containing conditions.

Methodological caution: heparin can structurally alter the fibrils/oligomers being formed (polymorphism), which can change which seed species exist. Therefore, the observed functional switch could reflect altered seed populations rather than only a change in DnaJB1 “logic.” The heparin polymorphism literature supports this general concern.

What is novel and why it matters (mechanistically)

The paper’s most valuable contribution is not just “DnaJB1 binds tau,” but the context-aware mapping of how a disordered, charged N-terminal fuzzy coat can govern functional inhibition in heparin-free settings, while heparin can act as an extrinsic polyanion that bridges binding and changes which tau species become seed-competent.

Translation caution: the work uses reductionist in vitro and HEK293T biosensor systems. While these systems can be powerful for mechanistic dissection, they can miss neuronal-scale cofactors, membrane trafficking dynamics, and the full JDP redundancy landscape.

Limitations and critical counterpoints (what could be misleading?)

ThT ≠ seed potency. The paper explicitly reports mismatches: DnaJB1 can delay/alter ThT-positive aggregation yet change inclusion formation/seeding differently. Therefore, any “inhibition” claim should be qualified to the specific readout.
Heparin-induced fibrils are structurally polymorphic and non-physiological relative to ex vivo disease fibrils, so the “heparin switch” may partly reflect altered seed ensembles.
Weak transient binding complicates affinity quantification (e.g., ITC often fails to detect binding to tau monomers without heparin; NMR indicates broadening rather than strong stable complexes). This can bias interpretation toward “indirect” or “ensemble” effects.
XL-MS is proximity-based and chemistry-limited. For example, DSS XL-MS lacks coverage for the DnaJB1 G/F region due to lysine depletion, so “no contact detected” is not equivalent to “no binding.”

Practical next steps (hypothesis-splitting experiments)

A. Distinguish “binding-mode competition” from “seed ensemble change.”

Use heparin competitors or heparin-mimicking polyanions that alter binding geometry without inducing identical fibril polymorphs, then re-run paired readouts: (i) DnaJB1 recruitment/binding to fibrils/oligomers and (ii) cell seeding potency.

Rationale from heparin polymorphism literature: heparin can change fibril structure ensembles; hence, comparing across seed ensembles is essential.

B. Resolve heparin’s direct interaction with DnaJB1 vs tau

Perform binding and XL-MS with defined polyanion size/charge regimes, keeping tau constant, to test whether DnaJB1’s recruitment mechanism is bridged chiefly via tau basic domains or via DnaJB1 basic patches.

The paper provides initial evidence that heparin alone binds DnaJB1 with nanomolar affinity and that heparin size affects detection and complex formation.

Interactive links (bespoke BGPT follow-ups)

Feedback:

Updated: April 29, 2026